Ryvu Therapeutics

The European biotech environment seems to be enjoying something of a revival but it has been a chastening week for three of the continent’s cancer-focused companies that have been forced to look at al

Poland’s biopharma sector is best known for its strengths in generics and biosimilars, with companies like Polpharma SA providing central Europe and beyond with a reliable flow of affordable off-pat

After years of slow progress, companies working in the field of NLRP3 inflammasome inhibitors are hoping to soon finally realize the promise of the novel drug class. The NLRP3 inflammasome is a multi-

BioNTech SE ’s deal to license two antibody-drug conjugates (ADCs) from Duality Biologics further expands the German biotech’s pipeline, which has grown rapidly thanks to its cash windfall from sale